Algert Global LLC Sells 14,091 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Algert Global LLC cut its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 32.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,501 shares of the company's stock after selling 14,091 shares during the quarter. Algert Global LLC's holdings in Twist Bioscience were worth $1,371,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in TWST. Van ECK Associates Corp boosted its holdings in Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after purchasing an additional 267 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Twist Bioscience during the third quarter valued at approximately $34,000. US Bancorp DE boosted its holdings in Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after purchasing an additional 601 shares in the last quarter. KBC Group NV boosted its holdings in Twist Bioscience by 71.4% during the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after purchasing an additional 1,226 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in Twist Bioscience by 19.9% during the fourth quarter. Blue Trust Inc. now owns 4,567 shares of the company's stock valued at $206,000 after purchasing an additional 757 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on TWST shares. Guggenheim reiterated a "buy" rating and issued a $50.00 target price on shares of Twist Bioscience in a research note on Tuesday, May 6th. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Barclays cut their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. The Goldman Sachs Group dropped their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $50.40.

Twist Bioscience Trading Down 0.2%

Shares of Twist Bioscience stock traded down $0.06 on Thursday, hitting $29.46. 415,981 shares of the company's stock traded hands, compared to its average volume of 965,897. The firm's 50-day moving average price is $38.11 and its two-hundred day moving average price is $43.46. The stock has a market capitalization of $1.77 billion, a PE ratio of -8.78 and a beta of 2.54. Twist Bioscience Co. has a one year low of $28.48 and a one year high of $60.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The firm had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. On average, research analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 689 shares of the stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $25,940.85. Following the transaction, the insider now directly owns 110,849 shares of the company's stock, valued at $4,173,464.85. This represents a 0.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Emily M. Leproust sold 2,402 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $98,265.82. Following the completion of the transaction, the chief executive officer now directly owns 662,692 shares in the company, valued at approximately $27,110,729.72. This represents a 0.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,991 shares of company stock valued at $742,654. Insiders own 3.01% of the company's stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.